Table. Study Population Tested for SARS-CoV-2 RNA by RT-PCR, Tested for Antibodies Against SARS-CoV-2, and Tested for Antibodies After Positive RT-PCR Result.
| Characteristic | Patients, No. (%) | |||||
|---|---|---|---|---|---|---|
| Tested for SARS-CoV-2 RNA with RT-PCR | Tested for antibodies against SARS-CoV-2 | With positive RT-PCR results then tested for antibodies | ||||
| RT-PCR negative (n = 267 502) | RT-PCR positive (n = 10 065) | IgG negative (n = 13 129) | IgG positive (n = 1161) | IgG negative (n = 121) | IgG positive (n = 365) | |
| Sex | ||||||
| Female | 144 968 (54.2) | 5165 (51.3) | 6970 (53.1) | 605 (52.1) | 70 (57.9) | 184 (50.4) |
| Male | 122 534 (45.8) | 4900 (48.7) | 6159 (46.9) | 556 (47.9) | 51 (42.1) | 181 (49.6) |
| Age group, y | ||||||
| 0-18 | 27 676 (10.3) | 1019 (10.1) | 369 (2.81) | 34 (2.93) | 3 (2.48) | 4 (1.10) |
| 19-39 | 72 226 (27.0) | 3865 (38.4) | 3610 (27.5) | 349 (30.1) | 49 (40.5) | 113 (31.0) |
| 40-49 | 34 276 (12.8) | 1606 (16.0) | 2557 (19.5) | 214 (18.4) | 13 (10.7) | 62 (17.0) |
| 50-59 | 41 362 (15.5) | 1547 (15.4) | 2643 (20.1) | 223 (19.2) | 15 (12.4) | 79 (21.6) |
| 60-69 | 43 749 (16.4) | 1032 (10.3) | 2318 (17.7) | 208 (17.9) | 17 (14.0) | 52 (14.2) |
| ≥70 | 48 213 (18.0) | 996 (9.90) | 1632 (12.4) | 133 (11.5) | 24 (19.8) | 55 (15.1) |
Abbreviations: IgG, immunoglobin G; RT-PCR, reverse transcription–polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.